Antihemophilic Factor Market Players:
- Genetech
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Biogen Idec
- Bayer AG
- Octapharma
- Novo Nordisk
- Baxter
- Kedrion
- Pfizer Inc.
- Sanofi SA
- CSL Behring
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of antihemophilic factor is evaluated at USD 3.64 billion.
The global antihemophilic factor market size was worth around USD 3.42 billion in 2025 and is set to register a CAGR of more than 7.2%, exceeding USD 6.85 billion revenue by 2035.
North America is projected to command a 53% share of the antihemophilic factor market by 2035, supported by an advanced healthcare ecosystem, high R&D spending, and strong biologics policies owing to the expanding elderly population and rising Medicare Advantage penetration.
Key players in the market include Genetech, Biogen Idec, Bayer AG, Octapharma, Novo Nordisk, Baxter, Kedrion, Pfizer Inc., Sanofi SA, CSL Behring.
